NASDAQ:TRVN

Trevena - TRVN Stock Forecast, Price & News

$0.15

0.00 (-0.91%)

(As of 09/30/2022 09:02 PM ET)

Add

Compare

Today's Range: $0.15
▼
$0.17
50-Day Range: $0.15
▼
$0.27
52-Week Range: $0.15
▼
$1.33

Volume: 607,500 shs
Average Volume: 1.33 million shs
Market Capitalization: $26.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.50

Trevena MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 879.1% Upside
$1.50 Price Target
Short Interest: Healthy
1.97% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.68
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.36) to ($0.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

1026th out of 1,095 stocks

Pharmaceutical Preparations Industry

507th out of 547 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $1.50, Trevena has a forecasted upside of 879.1% from its current price of $0.15.
Amount of Analyst Coverage
Trevena has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.97% of the outstanding shares of Trevena have been sold short.
Short Interest Ratio / Days to Cover
Trevena has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Trevena has recently decreased by 3.38%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Trevena does not currently pay a dividend.
Dividend Growth
Trevena does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TRVN.

1.5

News and Social Media Coverage

News Sentiment
Trevena has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Trevena this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for TRVN on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Trevena to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trevena insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.60% of the stock of Trevena is held by insiders.
Percentage Held by Institutions
Only 12.34% of the stock of Trevena is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Trevena are expected to grow in the coming year, from ($0.36) to ($0.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trevena is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trevena is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Trevena has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Trevena (NASDAQ:TRVN) Stock

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

TRVN Stock News Headlines

September 30, 2022 | americanbankingnews.com

Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

September 7, 2022 | benzinga.com

Trevena (TRVN) – Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference - Benzinga

September 7, 2022 | finance.yahoo.com

Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference

August 30, 2022 | msn.com

‘Red Sonja’: Oliver Trevena Boards Millennium Media Comic Book Film

August 18, 2022 | bizjournals.com

Venus Williams' nutrition company Happy Viking raises $2M - Bizwomen - The Business Journals

August 16, 2022 | finance.yahoo.com

What Makes Trevena (TRVN) a New Buy Stock

August 13, 2022 | benzinga.com

Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022 - Benzinga

August 13, 2022 | seekingalpha.com

Trevena, Inc's (TRVN) CEO Carrie Bourdow on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

August 12, 2022 | finance.yahoo.com

We're A Little Worried About Trevena's (NASDAQ:TRVN) Cash Burn Rate

August 12, 2022 | seekingalpha.com

Trevena GAAP EPS of -$0.09 beats by $0.01 (NASDAQ:TRVN) - Seeking Alpha

August 11, 2022 | finance.yahoo.com

Trevena Reports Second Quarter 2022 Results and Provides Business Update - Yahoo Finance

August 11, 2022 | finance.yahoo.com

Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2022 | seekingalpha.com

Trevena Q2 2022 Earnings Preview (NASDAQ:TRVN) - Seeking Alpha

August 10, 2022 | nasdaq.com

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates - Nasdaq

August 8, 2022 | finance.yahoo.com

Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022 - Yahoo Finance

August 8, 2022 | globenewswire.com

Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022 - GlobeNewswire

August 8, 2022 | finance.yahoo.com

Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022

August 5, 2022 | bizjournals.com

Lab Notes: Wistar Institute gets $5M NCI grant extension; Aclaris expands management team - The Business Journals

August 5, 2022 | nasdaq.com

Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates - Nasdaq

July 30, 2022 | benzinga.com

Trevena's Pain Management Drug Shows Better Cognitive Function Than Morphine - Benzinga

July 29, 2022 | streetinsider.com

Trevena, Inc. Announces Registered Direct Offering of Preferred Stock - StreetInsider.com

July 29, 2022 | finance.yahoo.com

Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock

July 29, 2022 | benzinga.com

Trevena shares are trading lower after the company announced a 8,000,000 share registered direct offering - Benzinga

July 29, 2022 | finance.yahoo.com

Trevena, Inc. Announces Registered Direct Offering of Preferred Stock

July 29, 2022 | bizjournals.com

Trevena cuts workforce by 25% to preserve cash for new product advancement - Philadelphia Business Journal - The Business Journals

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

TRVN Company Calendar

Last Earnings: 8/11/2022
Today: 10/03/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TRVN
CUSIP: N/A
CIK: 1429560
Web: www.trevena.com
Phone: (610) 354-8840
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $1.50
High Stock Price Forecast: $1.50
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +879.1%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,590,000.00
Net Margins: N/A
Pretax Margin: -29,547.00%
Return on Equity: -103.82%
Return on Assets: -78.53%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 5.87
Quick Ratio: 5.55

Sales & Book Value

Annual Sales: $570,000.00
Price / Sales: 46.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.39 per share
Price / Book: 0.39

Miscellaneous

Outstanding Shares: 173,681,000
Free Float: 167,428,000
Market Cap: $26.61 million
Optionable: Optionable
Beta: 1.83

Key Executives

Ms. Carrie L. Bourdow (Age 59)
Pres, CEO & Director
Comp: $920.39k

Mr. Barry Shin (Age 50)
Sr. VP & CFO
Comp: $609.94k

Dr. Mark A. Demitrack (Age 64)
Sr. VP & Chief Medical Officer
Comp: $641.3k

Dr. Howard A. Rockman M.D.
Scientific Founder, Consultant and Member of Scientific Advisory Board

Mr. Joel Solomon
VP, Head of Legal, Chief Compliance Officer & Corp. Sec.

Mr. Michael Catalano
VP of Marketing

Mr. Robert T. Yoder (Age 56)
Sr. VP, Chief Bus. Officer & Head of Commercial Operations

Ms. Patricia M. Drake (Age 56)
Sr. VP & Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TRVN Stock - Frequently Asked Questions

What is Trevena's stock price forecast for 2022?: 0 brokerages have issued 1 year price targets for Trevena's stock. Their TRVN share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 879.1% from the stock's current price.
View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts.
How have TRVN shares performed in 2022?: Trevena's stock was trading at $0.5830 at the start of the year. Since then, TRVN shares have decreased by 73.7% and is now trading at $0.1532.
View the best growth stocks for 2022 here.
When is Trevena's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our TRVN earnings forecast.
How were Trevena's earnings last quarter?: Trevena, Inc. (NASDAQ:TRVN) released its quarterly earnings data on Thursday, August, 11th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02.

What other stocks do shareholders of Trevena own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).
What is Trevena's stock symbol?: Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How do I buy shares of Trevena?: Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Trevena's stock price today?: One share of TRVN stock can currently be purchased for approximately $0.15.
How much money does Trevena make?: Trevena (NASDAQ:TRVN) has a market capitalization of $26.61 million and generates $570,000.00 in revenue each year. The biopharmaceutical company earns $-51,590,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.
How can I contact Trevena?: Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com.

This page (NASDAQ:TRVN) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Trevena - TRVN Stock Forecast, Price & News

Trevena MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows